Dr. Vikrant Upadhyay, PhD

Multiple Myeloma Researcher

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@npunwani Would you also recommend D-R Mx in dara-exposed Te-NDMM pts who are excluded in AURIGA?

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

👀 OS data from CARTITUDE-4 (cilta-cel CAR-T versus #MMsm standard therapies in 1-3 lines).

This is WONDERFUL to see!! Looking forward to hearing the ODAC meeting later this week... and no doubt the manuscript that is in preparation!

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@szusmani

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@SusanBal9 @bdermanmd Thank you Dr. Susan for the great presentation. Do you think GPRC5D CAR-Ts can also lead to secondary malignancies as seen with BCMA or CD19 targeting CAR-Ts?

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@jmikhaelmd CARTITUDE-4 showed HR of 0.15 in triple-class refractory pts. Does that indicate anti-CD38 mAb in NDMM and cilta-cel in 2L is more plausible sequencing?

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@Transplant_Doc CARTITUDE-4 showed HR of 0.15 in triple-class refractory pts. Does that indicate anti-CD38 mAb in NDMM and cilta-cel in 2L is more plausible sequencing?

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@DrSStern CARTITUDE-4 showed HR of 0.15 in triple-class refractory pts. Does that indicate anti-CD38 mAb in NDMM and cilta-cel in 2L is more plausible sequencing?

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@szusmani @myelomatips @bhemato @Dr_AdrianaRossi @SagarLonialMD Indeed...CARTITUDE-4 showed HR of 0.15 in triple-class refractory pts. Does that indicate anti-CD38 mAb in NDMM and cilta-cel in 2L is more plausible sequencing?

[Joseph Mikhael @jmikhaelmd]

No LINK in the chain broken? Can we give a bispecific longer term less frequently? Linvoseltamab phase 2 is trying to deliver with an ORR 71% and only 2 step up doses with CRS in less than 50% with one patient grade 3. #ASCO23 #MMSM #MedIQ23ASCO

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@Abdallah81MD Many thanks for the insight...

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@DrRakeshPopat May I know your thoughts on ASCT in near future as the new therapeutics are reaching 1L treatment of MM, like CAR-Ts, bispecifics and quad regimens...

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@nihardesai7 @myelomaMD @MayoMyeloma @MM_Hub @HCC_HemeCancer @faheema_hasan @NicoGagelmann @DrNikitaMehra @chepsyphilip @punitjn @Prasshmehta For sure. However, as the new therapeutics are reaching 1L treatment of MM, like CAR-Ts, bispecifics and quad regimens - what could be the place for ASCT in MM in future?

[Vibha Sharma @ScripRegVibha]

Among all drugs supported under EMA’s PRIME scheme, Janssen’s Tecvayli (teclistamab) underwent the fastest regulatory review – just 154 days. Incredible story + infographic from @ScripRegNeena tracks review times of all approved drugs under PRIME. ($)
https://t.co/w6Z5qrn9dR

[Faiz Anwer MD @FaizAnwerMD1]

Ide-CEL CAR T-Cell Therapy Effective in Multiple Myeloma Among Patients with Comorbidities – Consult QD https://t.co/VNMpqt9iM5

[Vincent Rajkumar @VincentRK]

4/ Myeloma is not one disease.

Myeloma is at least 6 or more cytogenetically distinct disease. The Multiple Myelomas. @NatRevClinOncol https://t.co/eyvoh3tslw

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@bhemato @GKaurMD @szusmani @JoshuaRichterMD @myelomatips @myelomaMD @SagarLonialMD @PlasmaCellPete @DrKrinaPatel @TomBmt133 @AjaiChari @NoopurRajeMD Is there a requirement for hospitalization in the first cycle?

[Joshua Richter, MD, FACP @JoshuaRichterMD]

Coming up soon with @SantiagoThibaud @MyelomaTeacher @HealthtreeMM @TischCancer @MountSinaiNYC …. Registration information below !

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@dranupjdevasia @HCC_HemeCancer @nihardesai7 @faheema_hasan @drsanjeev1980 @punitjn Just curious, how is now the decision made to choose between teclistamab and CAR-Ts?

[Dr. Vikrant Upadhyay, PhD @VUMolekule]

@szusmani @JoshuaRichterMD @myelomatips @bhemato @myelomaMD @SagarLonialMD @PlasmaCellPete @DrKrinaPatel @TomBmt133 @AjaiChari @NoopurRajeMD So now how is the decision made on picking CAR-T vs teclistamab?